Banque Pictet & Cie 13F: Adds $5M to Medline (MDLN) Stake

Banque Pictet & Cie boosted its holdings in Medline Inc. (NasdaqGS: MDLN) during the quarter, according to a Form 13F filing with the SEC on October 16, 2026. The firm acquired an additional 142,939 shares, growing its stake by 1.95% to reach 7,455,089 shares. The reported value of the position stood at approximately $258,691,588 at the time of the filing. Medline shares closed at $35.96 on the filing date.

MDLN Medline Inc.

$35.19 ▼ -13.37% year to date

1M 3M YTD

Daily close · Oct 19, 2026

What Changed in Banque Pictet & Cie's Medline Inc. Position

The recent SEC disclosure shows that Banque Pictet & Cie lifted its investment in Medline from 7,312,150 shares up to 7,455,089 shares. This 1.95% increase added 142,939 shares to the portfolio. The total value of the holdings reached $258,691,588.

Other Institutional Activity in Medline Inc.

Other large investors adjusted their holdings in the medical supply company around the same period. Carlyle Group Inc. held steady with 187,083,713 shares valued at $6,583,475,603. Blackstone Inc reduced its position by 22,404,953 shares, ending with 101,791,008 shares worth about $3,582,025,431 after an 18.0% cut. H&F Corporate Investors X, Ltd. cut its stake by 15,599,963 shares to finish with 70,874,326 shares valued at $2,494,067,434 following an 18.0% reduction. Lone Pine Capital Llc grew its holdings by 9,179,113 shares, ending with 20,968,367 shares worth about $737,876,805 after a 77.9% increase. Massachusetts Financial Services Co. grew its holdings by 8,319,493 shares, ending with 19,888,806 shares worth about $699,887,055 after a 71.9% increase.

Medline Inc. Stock Up 11.2%

Medline shares recently traded around $35.19 as of October 20, 2026, sitting about 2.1% below the $35.96 close recorded on the October 16 filing date. The company operates from its headquarters in Northfield, Illinois, manufacturing medical and surgical supplies for hospitals, surgery centers, and nursing homes across the United States and internationally.

Recent Earnings

The company posted trailing twelve month revenue of $29,938,999,296 alongside earnings of $0.8 per share. Profitability metrics include a net margin of 2.3% and a return on equity of 4.9%. The balance sheet shows a current ratio of 4.333 and a quick ratio of 2.45, with a debt-to-equity ratio of 66.258. The company is scheduled to release its next financial results on November 4, 2026.

Insider Buying and Selling at Medline Inc.

Gic Private Ltd, a beneficial owner of more than 10% of a class of security, executed multiple transactions prior to the filing. On August 7, 2026, the insider sold 590,284 shares at an average price of $35.58 for a total value of $21,002,305. On August 14, 2026, the insider sold 1,600,000 shares at $35.80 worth $57,280,000. On October 6, 2026, the insider sold 20,678,630 shares valued at $721,644,227. On October 8, 2026, the insider sold 7,816,987 shares at $35.15 worth $274,767,093. None of these transactions were reported as part of a Rule 10b5-1 plan.

Analysts Set New Price Targets

Wall Street research firms have updated their outlooks on the stock through recent months. On August 11, 2026, Tigress Financial maintained its buy rating while lowering its price target from $62.00 to $55.00. On August 12, 2026, JP Morgan maintained an overweight rating and adjusted its target from $53.00 down to $46.00. On August 27, 2026, BTIG reiterated a buy rating with a steady target of $55.00. On September 25, 2026, UBS maintained a buy rating while reducing its target from $45.00 to $43.00. On October 9, 2026, Barclays maintained an overweight rating, lowering its target from $45.00 to $43.00.

About Medline Inc.

Medline Inc. produces medical and surgical products utilized in healthcare facilities, ranging from large hospitals to local physician offices. It operates through two primary segments, Medline Brand and Supply Chain Solutions, handling everything from surgical gear and front line care supplies to laboratory diagnostics. Institutional holdings and insider transactions continue to draw attention as the firm approaches its next earnings update.

Bottom Line

Market participants will be watching for the upcoming earnings report on November 4, 2026, to gauge the company's financial trajectory. Further regulatory filings will reveal how institutional investors adjust their positions moving forward.